Literature DB >> 32050722

Nucleoside Diphosphate Kinase B Contributes to Arrhythmogenesis in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with Arrhythmogenic Right Ventricular Cardiomyopathy.

Fanis Buljubasic1,2, Ibrahim El-Battrawy1,2, Huan Lan3, Santosh K Lomada4, Anupriya Chatterjee4, Zhihan Zhao1,2, Xin Li1, Rujia Zhong1, Qiang Xu1, Mengying Huang1, Zhenxing Liao1, Siegfried Lang1,2, Lukas Cyganek2,5, Xiaobo Zhou1,2,3, Thomas Wieland2,4, Martin Borggrefe1,2, Ibrahim Akin1,2.   

Abstract

BACKGROUND: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a rare, inheritable cardiac disorder characterized by ventricular tachyarrhythmias, progressive loss of cardiomyocytes with fibrofatty replacement and sudden cardiac death. The exact underlying mechanisms are unclear.
METHODS: This study investigated the possible roles of nucleoside diphosphate kinase B (NDPK-B) and SK4 channels in the arrhythmogenesis of ARVC by using human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).
RESULTS: In hiPSC-CMs from a patient with ARVC, the expression levels of NDPK-B and SK4 channels were upregulated, the cell automaticity was increased and the occurrence rate of arrhythmic events was enhanced. Recombinant NDPK-B applied into hiPSC-CMs from either healthy donors or the patient enhanced SK4 channel current (ISK4), cell automaticity and the occurrence of arrhythmic events, whereas protein histidine phosphatase 1 (PHP-1), a counter actor of NDPK-B, prevented the NDPK-B effect. Application of PHP-1 alone or a SK4 channel blocker also reduced cell automaticity and arrhythmic events.
CONCLUSION: This study demonstrated that the elevated NDPK-B expression, via activating SK4 channels, contributes to arrhythmogenesis in ARVC, and hence, NDPK-B may be a potential therapeutic target for treating arrhythmias in patients with ARVC.

Entities:  

Keywords:  SK4 channel; arrhythmia; arrhythmogenic right ventricular cardiomyopathy; human-induced pluripotent stem cell-derived cardiomyocyte; nucleoside diphosphate kinase

Year:  2020        PMID: 32050722      PMCID: PMC7073527          DOI: 10.3390/jcm9020486

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  20 in total

Review 1.  Interaction of nucleoside diphosphate kinase B with heterotrimeric G protein betagamma dimers: consequences on G protein activation and stability.

Authors:  Thomas Wieland
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-03       Impact factor: 3.000

2.  Electrophysiological abnormalities precede overt structural changes in arrhythmogenic right ventricular cardiomyopathy due to mutations in desmoplakin-A combined murine and human study.

Authors:  John Gomes; Malcolm Finlay; Akbar K Ahmed; Edward J Ciaccio; Angeliki Asimaki; Jeffrey E Saffitz; Giovanni Quarta; Muriel Nobles; Petros Syrris; Sanjay Chaubey; William J McKenna; Andrew Tinker; Pier D Lambiase
Journal:  Eur Heart J       Date:  2012-01-11       Impact factor: 29.983

3.  Electrical dysfunctions in human-induced pluripotent stem cell-derived cardiomyocytes from a patient with an arrhythmogenic right ventricular cardiomyopathy.

Authors:  Ibrahim El-Battrawy; Zhihan Zhao; Huan Lan; Lukas Cyganek; Christoph Tombers; Xin Li; Fanis Buljubasic; Siegfried Lang; Malte Tiburcy; Wolfram-Hubertus Zimmermann; Jochen Utikal; Thomas Wieland; Martin Borggrefe; Xiao-Bo Zhou; Ibrahim Akin
Journal:  Europace       Date:  2018-06-01       Impact factor: 5.214

4.  Reversible histidine phosphorylation in mammalian cells: a teeter-totter formed by nucleoside diphosphate kinase and protein histidine phosphatase 1.

Authors:  Thomas Wieland; Hans-Jörg Hippe; Katrin Ludwig; Xiao-Bo Zhou; Michael Korth; Susanne Klumpp
Journal:  Methods Enzymol       Date:  2010-03-01       Impact factor: 1.600

5.  Arrhythmogenic Cardiomyopathy: Electrical and Structural Phenotypes.

Authors:  Deniz Akdis; Corinna Brunckhorst; Firat Duru; Ardan M Saguner
Journal:  Arrhythm Electrophysiol Rev       Date:  2016-08

Review 6.  Genetics of arrhythmogenic right ventricular cardiomyopathy: a practical guide for physicians.

Authors:  Frank I Marcus; Sue Edson; Jeffrey A Towbin
Journal:  J Am Coll Cardiol       Date:  2013-03-14       Impact factor: 24.094

7.  Maximum diastolic potential of human induced pluripotent stem cell-derived cardiomyocytes depends critically on I(Kr).

Authors:  Michael Xavier Doss; José M Di Diego; Robert J Goodrow; Yuesheng Wu; Jonathan M Cordeiro; Vladislav V Nesterenko; Héctor Barajas-Martínez; Dan Hu; Janire Urrutia; Mayurika Desai; Jacqueline A Treat; Agapios Sachinidis; Charles Antzelevitch
Journal:  PLoS One       Date:  2012-07-05       Impact factor: 3.240

8.  SK4 K+ channels are therapeutic targets for the treatment of cardiac arrhythmias.

Authors:  Shiraz Haron-Khun; David Weisbrod; Hanna Bueno; Dor Yadin; Joachim Behar; Asher Peretz; Ofer Binah; Edith Hochhauser; Michael Eldar; Yael Yaniv; Michael Arad; Bernard Attali
Journal:  EMBO Mol Med       Date:  2017-04       Impact factor: 12.137

Review 9.  Alterations in reversible protein histidine phosphorylation as intracellular signals in cardiovascular disease.

Authors:  Thomas Wieland; Paul V Attwood
Journal:  Front Pharmacol       Date:  2015-08-21       Impact factor: 5.810

10.  Histidine phosphorylation relieves copper inhibition in the mammalian potassium channel KCa3.1.

Authors:  Shekhar Srivastava; Saswati Panda; Zhai Li; Stephen R Fuhs; Tony Hunter; Dennis J Thiele; Stevan R Hubbard; Edward Y Skolnik
Journal:  Elife       Date:  2016-08-19       Impact factor: 8.140

View more
  2 in total

Review 1.  Small and Intermediate Calcium Activated Potassium Channels in the Heart: Role and Strategies in the Treatment of Cardiovascular Diseases.

Authors:  David Weisbrod
Journal:  Front Physiol       Date:  2020-11-23       Impact factor: 4.566

Review 2.  Takotsubo Syndrome: Translational Implications and Pathomechanisms.

Authors:  Xuehui Fan; Guoqiang Yang; Jacqueline Kowitz; Ibrahim Akin; Xiaobo Zhou; Ibrahim El-Battrawy
Journal:  Int J Mol Sci       Date:  2022-02-10       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.